Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in -arrestin recruitment and faster agonist dissociation rates
Strengthened Enforcement: The Central Drugs Standard Control Organisation(CDSCO) must move from reactive raids to a proactive system for tracking Schedule-H drugs, possibly using blockchain or a centralized digital prescription registry
CagriSemas two-peptide design makes its pharmacology and dosing inherently different from a single-molecule agent, so equivalent numbers do not mean equivalent products
Put simply, in the lab, GLP-1 drugs only fed tumor cells that had the GLP-1 receptor
Under the medical direction of Dr
doi: 10.1038/nn.4540, 150 van BloemendaalL.RgI